PHC2 as a novel predictive biomarker and therapeutic target for cisplatin resistance in lung adenocarcinoma. [PDF]
Pan X, Sun X, Xing Y, Zhang Z, Shi M.
europepmc +1 more source
Metabolic reprogramming and cisplatin resistance: the emerging role of Pyruvate Dehydrogenase Kinases (PDKs). [PDF]
Shaheeda A, Kabekkodu SP.
europepmc +1 more source
Cisplatin resistance in oral squamous cell carcinoma: mechanisms, reversal strategies, and emerging technologies. [PDF]
Shi Y, Liao W, Bai G, Chen B.
europepmc +1 more source
Effect of electronic cigarette aerosols on cisplatin resistance in head and neck cancer cells: a collaborative replication study. [PDF]
Emma R +20 more
europepmc +1 more source
Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer. [PDF]
Yang C +9 more
europepmc +1 more source
CDK4 Mediates Cisplatin Resistance in Renal Cell Carcinoma (RCC) Cells by Regulating the ASH1L-CTR1 Axis. [PDF]
Zeng W +7 more
europepmc +1 more source
Mitochondrial dynamics in cisplatin resistance: molecular mechanisms and therapeutic targeting. [PDF]
Huang W, Sun W, Yang Z, Li Y, Wang Z.
europepmc +1 more source
Single-cell insights into cisplatin resistance mechanisms in bladder cancer tumor microenvironment. [PDF]
Xu L +5 more
europepmc +1 more source
CircCDK6 Regulates Stemness Maintenance and Cisplatin Resistance in Lung Adenocarcinoma via the Wnt/β-Catenin Signaling Pathway. [PDF]
Li D, Shen Y, Wang L, Sun H, Wang Y.
europepmc +1 more source
BMAL1 Drives Cisplatin Resistance in Non-Small Cell Lung Cancer Via Lactate-MRP1 Signaling Pathway. [PDF]
Shi Z +11 more
europepmc +1 more source

